idarucizumab Injection

Brand(s)
Praxbind
Category(s)
prescription
SPL Type(s)
Human Prescription
Master SPL
Boehringer Ingelheim Pharmaceuticals, Inc. (2015-10-28)
Oldest Current Product
2015-10-21
License(s)
BLA
RxNORM
INJECTION\IDARUCIZUMAB
SPL Active
INTRAVENOUS\INJECTION\IDARUCIZUMAB
SPL Moiety
INTRAVENOUS\INJECTION\IDARUCIZUMAB

product(s) by strength(s)

50 ml idarucizumab 50 mg/ml injection

product(s)(s)

#idbrandcategorylabelerfirst marketedactive ingredient(s)routedose formapplicationspl
1005970197PraxbindBLABoehringer Ingelheim Pharmaceuticals, Inc.2015-10-21IDARUCIZUMABINTRAVENOUSINJECTION761025c7400f8a-dcf4-a6df-6d07-983081b1bf34

spl(s)

#idtitlecategorytypelabelerlabeler actlast updateversionproduct(s)
1c7400f8a-dcf4-a6df-6d07-983081b1bf34 (view SPL)These highlights do not include all the information needed to use PRAXBIND safely and effectively. See full prescribing information for PRAXBIND. PRAXBIND (idarucizumab) injection, for intravenous useInitial U.S. Approval: 2015prescriptionHuman PrescriptionBoehringer Ingelheim Pharmaceuticals, Inc.ANALYSIS, API MANUFACTURE, LABEL, PACK2015-10-282005970197

Data from: LOINC, MTHSPL, NDFRT, NCIT, RxNORM, UNII